Physician profile
Edward Robinson
NPI 1306279955
$6,540.06
in general payments reported to CMS, 2019-2025
30 companies · $4,339 in 2025
The $4,339 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.78 · 2020: $37.97 · 2021: $421 · 2022: $362 · 2023: $653 · 2024: $699 · 2025: $4,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,688 · Food and Beverage: $1,750 · Travel and Lodging: $1,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,687.86 |
| Food and Beverage | $1,749.56 |
| Travel and Lodging | $1,254.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,710.16 | 2025 | |
| Olympus Corporation of The Americas | $1,090.64 | 2025 | Spiration Valve System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.77 | 2021-2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $314.36 | 2022-2025 | Fasenra, Tezspire |
| Jazz Pharmaceuticals INC. | $299.49 | 2020-2025 | |
| Glaxosmithkline, LLC. | $231.68 | 2021-2024 | Arexvy, Nucala |
| Insmed, INC. | $153.01 | 2021-2024 | Arikayce |
| Paratek Pharmaceuticals, INC. | $124.96 | 2023 | Nuzyra |
| Heron Therapeutics, INC. | $124.47 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $120.09 | 2024-2025 | Lumryz |
| Actelion Pharmaceuticals US, INC. | $118.71 | 2024 | Opsumit, Uptravi |
| Planmeca USA, INC. | $109.44 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.37 | 2023-2024 | Glassia, Cuvitru |
| Axsome Therapeutics, INC. | $97.83 | 2025 | Sunosi |
| Merck Sharp & Dohme LLC | $89.21 | 2021-2024 | Winrevair, Dificid, Recarbrio |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $72.73 | 2025 | Inspire |
| Olympus America INC. | $68.50 | 2025 | Spiration Valve System |
| Grifols USA, LLC | $40.48 | 2021-2024 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $33.64 | 2025 | |
| Blueprint Medicines Corporation | $31.66 | 2023 | Ayvakit |
| Allergan, INC. | $26.78 | 2019 | |
| Genentech USA, INC. | $26.22 | 2022 | |
| Idorsia Pharmaceuticals US INC | $25.77 | 2025 | Quviviq |
| Alexion Pharmaceuticals, INC. | $18.90 | 2023 | Soliris |
| Bayer Healthcare Pharmaceuticals INC. | $15.85 | 2023 | |
| Zoll Respicardia, INC. | $15.50 | 2024 | Remede System |
| Ani Pharmaceuticals, INC. | $15.16 | 2025 | Purified Cortrophin Gel |
| Gilead Sciences, INC. | $14.86 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.47 | 2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $14.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.